Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to…
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)
April 28, 2025 04:00 ET | Source: BlackfinBio CHESHIRE, United Kingdom, April…
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025
April 28, 2025 03:00 ET | Source: EnteroBiotix EnteroBiotix Announces Oral Presentation…
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
April 26, 2025 10:00 ET | Source: Protara Therapeutics TARA-002 demonstrates 100%…
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
April 24, 2025 01:00 ET | Source: Zealand Pharma Press release –…
Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
April 23, 2025 03:00 ET | Source: Cytovation New funds provided largely…
InCred Wealth eyes the next phase of growth; ropes in Anu Bora to head the Family Office practice
MUMBAI, India , April 22, 2025 /PRNewswire/ -- InCred Wealth & Investment Services…
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
April 21, 2025 11:19 ET | Source: Achieve Life Sciences ORCA-3 Demonstrated…
Blue Mountain Solidifies Executive Leadership with Seasoned GTM Appointments to Drive Next Phase of Growth and Innovation
Industry & GTM Stalwarts Keith Pensabene and Christian Rockwell join leadership team,…
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
April 17, 2025 01:00 ET | Source: Addex Therapeutics Ad Hoc Announcement…